InVitria develops, manufactures, and markets recombinant, scalable, and sustainable products for cell culture, bio-manufacturing, and final product formulation. Their products include recombinant proteins and supplements used in biomanufacturing, vaccines, biologic medicines, cell therapies, gene therapies, and regenerative medicines. InVitria's solutions are designed to provide safe and effective alternatives to serum and serum proteins, eliminating animal-derived components and reducing risks of pathogen contamination. They offer personalized technical support to help customers in cell and gene therapy, vaccines, biomanufacturing, and final formulation achieve their goals. InVitria's products focus on performance, scalability, and sustainability in the biopharmaceutical industry.